Search

Xencor Inc

Slēgts

SektorsVeselības aprūpe

23.21 1.49

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

22.48

Max

23.41

Galvenie mērījumi

By Trading Economics

Ienākumi

-22M

-151M

Pārdošana

47M

51M

EPS

-0.29

Peļņas marža

-294.108

Darbinieki

260

EBITDA

109M

-12M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+31.75% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

166M

1.6B

Iepriekšējā atvēršanas cena

21.72

Iepriekšējā slēgšanas cena

23.21

Xencor Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. aug. 19:16 UTC

Shares of Xencor Inc. are modestly higher amid cautious broader market sentiment following a decline in U.S. retail sales for July.

2026. g. 13. aug. 19:21 UTC

Xencor Inc shares are lower today, with no specific news driving the decline. High trading volume suggests increased activity amid routine fluctuations.

2026. g. 12. aug. 19:56 UTC

Social Media

Xencor Inc shares are higher, supported by social media discussions valuing the company at $1.3 billion based on its ENPP3 asset potential.

2026. g. 11. aug. 19:26 UTC

Xencor Inc shares are advancing, continuing a four-session trend. Investors are focused on upcoming inflation reports that may influence market sentiment.

2026. g. 10. aug. 19:31 UTC

News

Xencor Inc shares are higher today, buoyed by increased institutional investments from Dimensional Fund Advisors and BVF Inc. IL.

2026. g. 7. aug. 23:16 UTC

Xencor Inc shares are higher in after-market trading, supported by decreased interest rate hike expectations following a Labor Department report on non-farm payrolls.

2026. g. 6. aug. 20:03 UTC

News

Xencor shares are higher as Cantor Fitzgerald raises its price target to $44, reflecting confidence in the company's pipeline and upcoming ESMO Congress presentation.

2026. g. 3. aug. 19:51 UTC

Xencor Inc's shares are declining, continuing a downward trend since Friday's close, despite a broader market rally in technology and airlines.

2026. g. 31. jūl. 20:03 UTC

Xencor Inc shares are lower, reversing earlier gains amid rising US Treasury yields and crude oil prices, contributing to inflation concerns and interest rate expectations.

2026. g. 30. jūl. 19:03 UTC

News
Social Media

Xencor Inc. gains following a $105 million settlement with Alexion, boosting investor confidence and extending its operating runway through 2028.

2026. g. 29. jūl. 19:36 UTC

Xencor Inc. shares are lower as broader market trends decline ahead of the Federal Reserve's policy announcement, amid rising oil prices and inflation concerns.

2026. g. 28. jūl. 20:07 UTC

Xencor Inc is gaining amid a strong Biotechnology sector, despite earlier declines. The stock has rebounded to settle near the upper end of its one-month range.

2026. g. 27. jūl. 19:11 UTC

Xencor Inc shares are higher today, reflecting a positive market environment despite earlier intraday pullbacks. No specific news was identified to explain the movement.

2026. g. 24. jūl. 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

2026. g. 22. jūl. 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

2026. g. 21. jūl. 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

2026. g. 20. jūl. 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Salīdzinājums

Cenas izmaiņa

Xencor Inc Prognoze

Cenas mērķis

By TipRanks

31.75% augšup

Prognoze 12 mēnešiem

Vidējais 30.29 USD  31.75%

Augstākais 44 USD

Zemākais 20 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Xencor Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

9

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat